||Y-27632 is a selective inhibitor of ROCKs including p160ROCK (Ki: 140 nM) and ROCK2 (IC50: 800 nM).
||RKI-1447 is a potent inhibitor of ROCK1 and ROCK2. It has anti-invasive and antitumor activities.
||Capivasertib (AZD5363) is a new-type orally available inhibitor of the serine/threonine protein kinase AKT (IC50s: 3/7/7 nM for Akt1/2/3).
||RKI-1313 was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion.
||Thiazovivin, a ROCK inhibitor (IC50: 0.5 μM), increases the survival rate of hESC.
||Tofacitinib citrate is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).
||AT13148 is an oral-active and ATP-competitive, multi-AGC kinase inhibitor for Akt1/2/3, p70S6K, PKA, and ROCKI/II.
||GSK429286A is a specific inhibitor of ROCK1/2 (IC50: 14/63 nM).
||Fasudil Hydrochloride is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.
||GSK180736A is an effective and selective GRK2 inhibitor (IC50: 0.77 μM) and >100-fold selectivity over other GRKs. It is a weak inhibitor of PKA (IC50: 30 μM), but highly effecti
||GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.
||ZINC00881524 is an effective and specific ROCK inhibitor.
||URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
||Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis.
||KD025 is an orally available, and specific ROCK2 inhibitor (IC50/Ki: 60/41 nM).
||Hydroxyfasudil hydrochloride is a ROCK1/2 inhibitor (IC50s: 0.73/0.72 μM).
||BDP5290 is a potent inhibitor of both ROCK and MRCK(IC50s of 5 nM, 50 nM, 10 nM and 100 nM for ROCK1, ROCK2, MRCKα and MRCKβ, respectively.)
||Ripasudil free base
||Ripasudil free base is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent.
||H-1152 is a potent, specific, ATP-competitive, and cell permeable ROCK inhibitor (Ki = 1.6 nM).
||Azaindole 1 (TC-S 7001) is a selective and ATP-competitive ROCK inhibitor with IC50 of 0.6 and 1.1 nM for human ROCK-1 and ROCK-2.
||Narciclasine, a natural product, modulates the Rho/Rho-kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity.
||SR-3677 is an effective and specific inhibitor of ROCK2 (IC50: ~3 nM).
||Ripasudil hydrochloride dihydrate
||Ripasudil (K-115) hydrochloride dihydrate is a specific ROCK inhibitor (IC50s: 51/19 nM for ROCK1/ROCK2).
||Cucurbitacin I, cytotoxic triterpenoid sterols isolated from plants, elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhi
||Rho-Kinase-IN-1 is a inhibitor of Rho kinase (ROCK) with Ki values of 30.5 and 3.9 nM for ROCK1 and ROCK2, respectively
||ROCK inhibitor-2 is a selective dual inhibitor of ROCK1 and ROCK2 (IC50s of 17 nM and 2 nM, respectively).
||ROCK2-IN-2 is a selective inhibitor of ROCK2(IC50 of <1 μM).
||Chroman 1 is an inhibitor of ROCK2 (IC50: 1 nM).
||CMPD101 is a membrane-permeable inhibitor of GRK2/3 (IC50: 18 nM and 5.4 nM) used for the study of heart failure. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and P
||Y-9738 is an agent of hypolipidemic.
||YAP/TAZ inhibitor-1 is an inhibitor of YAP/TAZ (IC50 of <0.100 μΜ in firefly luciferase assay).
||(1R,2S)-VU0155041 is a partial agonist of mGluR4(EC50 of 2.35 μM).
||Merestinib dihydrochloride is an effective and orally bioavailable c-Met inhibitor (Ki=2 nM). It has anti-tumor activities and also has potent activity against MST1R (IC50=11 nM),
||Netarsudil hydrochloride is an inhibitor of Rho-associated protein kinase (ROCK) and norepinephrine transporter (NET) with effective in intraocular pressure (IOP) reduction.
||SB-772077B dihydrochloride is an aminofurazan-based Rho kinase inhibitor (IC50s: 5.6 nM and 6 nM toward ROCK1 and ROCK2, respectively).